Features | Partner Sites | Information | LinkXpress
Sign In
SEEGENE
AB Sciex
RANDOX LABORATORIES

High-Tech Blood Test Predicts Premature Birth Risk

By Labmedica International staff writers
Posted on 27 Feb 2013
A blood test that predicts preterm birth harvests exosomes from a blood sample and looks for a specific biomarker fingerprint that indicates a high risk for preterm birth, even in women with no known risk factors.

NX PharmaGen (Louisville, KT, USA) has conducted early studies with maternal serum samples using its NeXosome Preterm Birth Assay. Two cohorts were balanced for age and subjects were asymptomatic with no known risk factors, such as hypertension, twins, or gestational diabetes. The average age was 28. In the study, a preterm birth was before 34 weeks and after 37 weeks was full-term.

As early as 15 weeks, the test could detect a risk for preterm birth. NX PharmaGen’s initial human studies also suggest the test could be used for early detection, sub-typing/staging, drug receptor presence/absence, and recurrence monitoring for cancer, including lung cancer, ovarian cancer, and brain cancer.

“If you harvest exosomes and open them up and look at their content, the protein content of a term pregnancy looks very different from a preterm pregnancy,” commented Brian Brohman, co-founder and chief business officer of NX Pharmagen.

The initial benefit of the NeXosome Preterm Birth Assay will allow doctors to move a patient from normal OBGYN care to a fetal medicine specialist.

“This is a tool to tell doctors where they should be spending extra time,” Brian Brohman said. “If you can extend the pregnancy on knowledge of a risk, you can save lots of money.”

Next steps for NX PharmaGen are assay optimization and validation. Brian Brohman said that it is too early to know which regulatory path the company will take: Clinical Laboratory Improvement Amendments a laboratory-developed test (CLIA LDT) and an US Food and Drug Administration (FDA; Silver Spring, MD, USA) approval.

The company is seeking patents on the biomarker pattern that indicates a high risk of premature birth and the method of harvesting exosomes from a blood sample.

Related Links:

NX PharmaGen




ADVANCED INSTRUMENTS
PURITAN MEDICAL
GREINER-BIO-ONE
BioConferenceLive

Channels

Clinical Chemistry

view channel
Image: The ICON 25 hCG point-of-care pregnancy test (Photo courtesy of Beckman Coulter).

Pregnancy Tests Evaluated During Early Gravidity

The predominant hormone human chorionic gonadotropin (hCG) variant in urine, hCG β core fragment (hCGβcf), has been demonstrated to cause false-negative results in qualitative point-of-care (POC) hCG devices.... Read more

Pathology

view channel
Image: Micrograph showing prostatic acinar adenocarcinoma, the most common form of prostate cancer (Photo courtesy of Zephron).

New Test Could Accurately Predict Prostate Cancer Recurrence

A test based on genetic signature and tumor oxygen levels, which boost the test’s accuracy, can predict whether a man is at high risk of prostate cancer recurrence. Prostate cancer is the most common... Read more

Industry News

view channel

Roche and Hitachi Renew Alliance in Diagnostics

Roche (Basel, Switzerland) and Hitachi (Tokyo, Japan) have renewed their alliance in the diagnostics business by 10-years for the joint development and manufacture of the next generation of instruments and workflow automation solutions for medical laboratories. The renewed alliance marks a significant milestone towards... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.